Introduction
A 56-year-old man presented in the fall of 2015 with left flank pain and hematuria. He was evaluated by his primary care physician, and a computed tomography (CT) scan showed nephrolithiasis, a left renal mass, significant lymphadenopathy in the left hilar region, small indeterminate pulmonary nodules, and small sclerotic lesions in the left femur and left humerus. He underwent a left radical nephrectomy with excision of retrocrural lymph nodes and retroperitoneal lymph node dissection. Pathology revealed a 9-cm unclassified renal cell carcinoma (RCC) with 40% sarcomatoid features and invasion into renal vein, perirenal fat, and hilar fat ( Figure 1A ). The tumor was graded as Fuhrman grade 4. The adrenal gland was involved by tumor. Three retrocrural and 5 interaortocaval lymph nodes were involved with carcinoma. Repeat CT scans postoperatively showed an enlarging right retrocrural lymph node that was not resected during surgery and new lung nodules. Surgical pathology was sent for further immunohistochemistry and next-generation sequencing. No actionable DNA mutations, copy number variants, or gene fusions were found. Messenger RNA expression analysis showed high expression of the kidney-specific biomarker CA IX at 35.3-fold of normal. Immunohistochemistry review revealed programmed death-ligand 1 (PD-L1) expression on 90% of tumor cells with 3þ intensity ( Figure 1B) . Moreover, PD-L1 tumor-infiltrating lymphocytes were present in 10% of the tumor sample with 2þ intensity. Given the presence of metastatic disease, the patient was started on treatment with sunitinib 50 mg orally daily for 4 weeks on and 2 weeks off schedule. Two months after initiating treatment of sunitinib, he experienced growing supraclavicular lymph nodes causing local pain. Repeat CT scans showed enlarging left supraclavicular (4 cm), paraesophageal (2.5 cm), right paraspinal (2 cm), bilateral retrocrural (2 cm), and retroperitoneal (2 cm) lymphadenopathy. In addition, there were growing pulmonary nodules and new liver metastatic disease. Figure 2 shows CT scans of the chest, abdomen, and pelvis at the time of progression. Second-line treatment with the programmed death-1 (PD-1) inhibitor, nivolumab (3 mg/kg intravenously every 2 weeks), was initiated. After 1 dose of nivolumab, the patient's supraclavicular lymphadenopathy was no longer palpable, and the associated pain subsided. Repeat CT scans after treatment with nivolumab showed partial response with marked improvement in lymphadenopathy and lung nodules ( Figure 3) . Some of the previously noted lymph nodes were completely resolved, and others were much smaller in size. In addition, there was a decrease in the size of pulmonary and liver metastases.
The patient is now 10 months into treatment with nivolumab for his unclassified RCC and continues to have a significant response. He has received palliative radiotherapy to metastatic disease in the left femoral head and left humerus at a dose of 20 Gy divided over
Clinical Practice Points Clinical Practice Points
Patients with unclassified renal cell carcinoma are generally diagnosed with high-grade tumors, are associated with highly aggressive biological behavior, and have poor clinical outcomes. In this brief report, we present a case of metastatic unclassified renal cell carcinoma with significant response to immune checkpoint inhibition.
The findings in this report suggest that further investigation is warranted for utilizing checkpoint inhibitors in patients with unclassified renal cell carcinoma, especially in case of high programmed death-ligand 1 expression.
5 fractions. He has an excellent quality of life and is able to function at the level prior to being diagnosed with metastatic unclassified kidney cancer.
Discussion
RCC is histologically classified as clear cell RCC, papillary RCC, chromophobe RCC, collecting duct RCC, or unclassified RCC.
1,2 Several reports have indicated significant differences in pathologic features and clinical outcomes among patients with different RCC histologic subtypes. 3, 4 Unclassified RCC is comprised of renal cortical epithelial neoplasms that could not be assigned to any of the other RCC subtypes based on histologic evaluation, and it constitutes 3% to 5% of cases of RCC. 1 Unclassified RCC is a category that encompasses a wide range of genetic alterations and histologic findings that might contain elements of other histologic subtypes of RCC or sarcomatoid features. Tumors with pure sarcomatoid or mixed sarcomatous and anaplastic features are also designated as unclassified RCC. These unclassified tumors are generally high-grade and have unrecognizable cell types. Studies evaluating unclassified RCC indicate that these neoplasms are associated with highly aggressive biological behavior and poor clinical outcomes. [5] [6] [7] [8] [9] [10] [11] [12] Patients tend to present with larger tumors and have increased risk of invasion to adjacent organs, increased risk for regional and nonregional lymph node metastasis, and increased risk for bone metastasis. 9 In addition, several studies have indicated that patients with unclassified RCC are more likely to present with higher grade and stage that are associated with shorter cancer-specific and overall survival compared with patients with clear-cell RCC. 7, 8 In this report, a patient with unclassified RCC developed progressive metastatic disease shortly after nephrectomy and retroperitoneal and retrocrural lymph node dissection. Next-generation sequencing did not reveal actionable mutations. Further immunohistochemistry testing showed 3þ PD-L1 expression on 90% of 
Conclusion
To our knowledge, there is limited data of treating patients with unclassified RCC with immune checkpoint inhibitor-based therapy. Here, we report a case of metastatic unclassified RCC with high PD-L1 tumor expression and a significant response to nivolumab. PD-L1 expression appears to predict response to PD-1/PDL-1 inhibitors in lung cancer and melanoma but not in metastatic clearcell RCC. [13] [14] [15] It is unclear whether PD-L1 expression may be a predictive marker of response to immune checkpoint inhibitors in noneclear-cell RCC, and particularly in the unclassified histotype. The findings in this report suggest that further investigation is warranted for utilizing checkpoint inhibitors upfront in this subgroup of patients with RCC who have limited therapeutic options, especially in case of high PD-L1 expression.
